| |JULY 202619responsibility towards patients whose lives depend on the safety and effectiveness of our medicines. In oncology, even the smallest variation can impact patient outcomes, which is why process standardization, data integrity, and regulatory compliance remain non-negotiable", says Rahul Batra.Backward integration also compresses costs at the source, the only sustainable way to make oncology medicines affordable without eroding margins. This has simultaneously made Beta Drugs a recognized contract manufacturing partner for leading pharmaceutical companies across India. Global Roadmap Rooted in AccessibilityBeta Drugs reaches more than 85 percent of corporate and government hospitals across India and has earned a place on Forbes Asia's "200 Best Under a Billion" list for four consecutive years, recognition that speaks as much to consistency as it does to scale. The international ambition, however, is where the next chapter gets compelling. Internationally, regulatory approvals span EAEU, Brazil's ANVISA, Colombia's INVIMA, and Mexico's COFEPRIS, with a scheduled EU GMP. Over 600 registrations are in the pipeline across Latin America, Asia-Pacific, MENA, Africa, and the CIS region. The COFEPRIS approval unlocks Mexico's 1.3-billion-dollar oncology formulation market. EAEU access spans Russia, Kazakhstan, Kyrgyzstan, Belarus, and Armenia simultaneously. "Our vision is to build a globally respected oncology company that combines scientific innovation, manufacturing excellence, and affordability, making advanced cancer treatments accessible to more patients worldwide. We will continue investing in R&D, complex oncology products, and next-generation therapies while strengthening our presence across regulated and emerging markets", says Varun Batra.The future of oncology will continue to be shaped by therapies that are not only clinically effective but also more accessible, patient-friendly, and economically sustainable. As treatment protocols evolve, the need for differentiated formulations, robust manufacturing capabilities, and reliable global supply chains will become increasingly critical. Beta Drugs has spent nearly four decades building these capabilities through continuous investment in complex oncology formulations, Novel Drug Delivery Systems (NDDS), backward-integrated manufacturing, and stringent quality standards. With a growing international footprint, a strong product pipeline, and an unwavering commitment to affordability, the company is well positioned to address the evolving needs of cancer care while ensuring that advanced oncology treatments reach more patients across the world. PO
< Page 9 | Page 11 >